You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023184012
Dec 202364010
Jan 20243708
Feb 20243806
Mar 20247004
Apr 20246206
May 20246805
Jun 20243802
Jul 20244005
Aug 20246407
Sep 20244004
Oct 20244804
Nov 202480011
Dec 202458012
Jan 202546013
Feb 20252206
Mar 2025007
Apr 2025003
May 2025007
Jun 2025007
Total9590139